Global healthcare company Abbott announced the launch of its latest-generation transcatheter aortic valve implantation (TAVI) system, NavitorTM, making available the minimally invasive device for people in India with severe aortic stenosis who are at high or extreme surgical risk.
Aortic stenosis is one of the most common and life-threatening heart valve diseases. It restricts blood flow through the aortic heart valve to the rest of the body, which can lead to heart failure and, in certain cases, sudden cardiac death.
In India, one in 40 people aged 75 and older have severe, symptomatic aortic stenosis. For these people, open-heart surgery is considered a high-risk procedure due to the potential complications stemming from age, frailty, or from having multiple comorbidities.
Navitor features a unique fabric cuff (NaviSeal™) that works with the cardiac cycle to reduce or eliminate a backflow of blood around the valve frame known as paravalvular leak, a common complication following TAVI procedures.
According to Abbott, the new device is the only self-expanding TAVI system with intra-annular (within the native valve) leaflets and large frame cells – features designed to help improve access to critical coronary arteries to facilitate future interventions to treat coronary artery disease. The new design additionally provides improved hemodynamics, or better blood flow.
Last updated: December 26th, 2025
